Cellectis S.A. (NASDAQ:CLLS) Short Interest Update

Cellectis S.A. (NASDAQ:CLLS - Get Free Report) was the target of a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 220,100 shares, a drop of 30.7% from the April 30th total of 317,800 shares. Based on an average daily volume of 314,600 shares, the short-interest ratio is currently 0.7 days. Currently, 0.5% of the company's shares are sold short.

Cellectis Trading Up 2.1%

Shares of NASDAQ:CLLS traded up $0.03 during midday trading on Thursday, hitting $1.46. The company had a trading volume of 107,910 shares, compared to its average volume of 143,397. Cellectis has a 12 month low of $1.10 and a 12 month high of $2.78. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The stock has a market cap of $81.15 million, a price-to-earnings ratio of -1.12 and a beta of 3.11. The firm has a fifty day simple moving average of $1.44 and a 200 day simple moving average of $1.55.

Cellectis (NASDAQ:CLLS - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.03). The business had revenue of $12.03 million for the quarter, compared to the consensus estimate of $12.71 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. On average, analysts predict that Cellectis will post -0.46 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CLLS. OLD Mission Capital LLC bought a new position in Cellectis during the first quarter worth about $31,000. Wells Fargo & Company MN lifted its holdings in Cellectis by 103.4% during the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock worth $44,000 after acquiring an additional 12,500 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Cellectis by 132.9% during the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 26,461 shares in the last quarter. Millennium Management LLC bought a new position in Cellectis during the fourth quarter worth about $962,000. Finally, B Group Inc. bought a new position in Cellectis during the fourth quarter worth about $5,547,000. 63.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CLLS. Wall Street Zen lowered Cellectis from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Barclays reduced their price target on Cellectis from $5.00 to $4.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.